It has a high level of scientific novelty when evaluating a nucleotide sequence of the genome of a Cuban isolation of hepatitis C virus, which possesses 8% of difference regarding others that were reported, besides the fact that this fragment is evaluated for the first time with a vaccinal approach. It has been patented nationally, and it has 4 publications, 2 of them in Vaccim and Biotechnol Appli Biochem magazine, which has a great impact.

The work evaluates the immunogenicity in individual way of different structural proteins of Hepatitis C virus initially starting from a Cuban isolation, expressed by recombinant via in a system of prokaryotic expression. These variants were very immunogenic in mice and rabbits stimulating high titers of antibodies. These antigens also reacted against human serums that contained antibodies against Hepatitis C virus.

In accordance with these results, there were built 8 variants of plasmid immunization with DNA which contained fragments of proteins of the individually cloned capsid. All these combinations were cloned in the plasmid pIDK (system of eukaryotic expression). The 8 variants produced specific detectable answers against the hepatitis C virus in mice. The answer of antibodies against the viral capsid showed viral immunologic specificity similar to the one detected in individuals infected by the Hepatitis C virus. The variant that includes the complete structural region showed levels of antibodies superior to those found in anti HCV positive individuals after the immunization, which demonstrates the biggest multiepitopic answer and the immunogenicity of these proteins using this technology, it was also evidenced a cellular answer of type CD4+ which associates with a benign course of this disease or with its resolution.